Johnson & Johnson said it would appeal the decision, CNBC reported.
The company's stock rose after hours because many on Wall Street were expecting it to have to pay at least $1.5 billion, according to Jefferies analyst Jared Holz.
The New Brunswick, N.J., company's stock was up 4% after hours. It had risen 0.8% in the regular session to $127.80.
Oklahoma Attorney General Mike Hunter had claimed that J&J and its pharmaceutical subsidiary, Janssen, helped worsen the opioid crisis in the state through aggressive marketing to doctors while downplaying the risks of the drugs.
Reuters reported that at trial, the state's lawyers had called J&J an opioid "kingpin" and argued that its marketing efforts created a public nuisance as doctors over-prescribed the drugs, leading to a surge in overdose deaths in Oklahoma.
J&J's Oklahoma counsel, John Sparks, said in a statement on Monday before the verdict that "not once did the state identify a single Oklahoma doctor who was misled by a single Janssen statement, nor did it prove that Janssen misleadingly marketed opioids or caused any harm in Oklahoma," Reuters reported.
Johnson & Johnson is a holding in Jim Cramer's Action Alerts PLUS charitable trust.
Save 57% With Our Labor Day Sale. Join Jim Cramer's Action Alerts PLUS investment club to become a smarter investor! Click here to sign up!